Pfizer Inc (PFE) 29.73 $PFE
Europe shares drift ahead of data; Asia gains
By YURI KAGEYAMA - AP - 37 mins ago
TOKYO (AP) — World markets were mostly higher Wednesday ahead of U.S. economic data while cheery earnings from major Japanese companies such as Honda Motor Co. boosted Asian stocks.
Chronic Plaque Psoriasis - Pipeline Review, H1 2014
M2 - 2 hrs 5 mins ago
Research and Markets (http://www.researchandmarkets.com/research/dpkjk3/chronic_plaque) has announced the addition of the "Chronic Plaque Psoriasis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Plaque Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Plaque Psoriasis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Plaque Psoriasis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Plaque Psoriasis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - AbGenomics International, Inc. - AbbVie Inc. - Actelion Ltd - Almirall, S.A. - ApoPharma Inc. - Biotest AG - Boehringer Ingelheim GmbH - Can-Fite BioPharma Ltd. - Eli Lilly and Company - GlaxoSmithKline plc - Incyte Corporation - Merck & Co., Inc. - Novartis AG - OPKO Health, Inc. - Pfizer Inc. - Sandoz Inc. For more information visit http://www.researchandmarkets.com/research/dp...nic_plaque
Fibromyalgia - Pipeline Review, H1 2014
M2 - 2 hrs 20 mins ago
Research and Markets (http://www.researchandmarkets.com/research/vjrklg/fibromyalgia) has announced the addition of the "Fibromyalgia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Fibromyalgia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fibromyalgia and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Fibromyalgia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Fibromyalgia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Eli Lilly and Company - Merck & Co., Inc. - Dainippon Sumitomo Pharma Co., Ltd. - Meda AB - Pfizer Inc. - Collegium Pharmaceutical, Inc. - Theravance, Inc. - e-Therapeutics plc - Concert Pharmaceuticals, Inc. - SWITCH Biotech LLC - EirGen Pharma Ltd. - Tonix Pharmaceuticals Holding Corp. For more information visit http://www.researchandmarkets.com/research/vj...bromyalgia
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H1 2014
M2 - 2 hrs 27 mins ago
Research and Markets (http://www.researchandmarkets.com/research/djdwhf/cognitive) has announced the addition of the "Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS) and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cognitive Impairment Associated With Schizophrenia (CIAS) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Eli Lilly and Company - Merck & Co., Inc. - Takeda Pharmaceutical Company Limited - Avineuro Pharmaceuticals, Inc. - Novartis AG - FORUM Pharmaceuticals Inc. - H. Lundbeck A/S - Pfizer Inc. - Suven Life Sciences Ltd. - Mithridion, Inc. - CoMentis, Inc. - Upsher-Smith Laboratories, Inc. - Siena Biotech S.p.A. - Dart NeuroScience LLC - Intra-Cellular Therapies, Inc. - Amarantus Bioscience Holdings, Inc. - Mnemosyne Pharmaceuticals, Inc. - SK Biopharmaceuticals Co., Ltd. - AbbVie Inc. - Saniona AB For more information visit http://www.researchandmarkets.com/research/djdwhf/cognitive
Most active New York Stock Exchange-traded stocks
AP - Tue Jul 29, 5:02PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Tue Jul 29, 5:02PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Merck, Pfizer Ramping R&D After Q2 Earnings Beat
at Investor's Business Daily - Tue Jul 29, 4:32PM CDT
Big pharmas Merck and Pfizer modestly beat Q2 estimates early Tuesday, and both guided the full year cautiously as they prepare for new drug launches. Merck stock rose 1.1%, but Pfizer stock fell 1.2%. Merck's (MRK) earnings totaled 85 cents a share,...
After Yesterday's Decline of 1.23%, Pfizer Offers Investors Better Value
Comtex SmarTrend(R) - Tue Jul 29, 3:41PM CDT
Pfizer (NYSE
FE) traded in a range yesterday that spanned from a low of $29.69 to a high of $30.49. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $29.78 on volume of 37.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Pfizer Set to Possibly Rebound After Yesterday's Selloff of 1.23%
Comtex SmarTrend(R) - Tue Jul 29, 3:41PM CDT
Pfizer (NYSE FE) traded in a range yesterday that spanned from a low of $29.69 to a high of $30.49. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $29.78 on volume of 37.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Pfizer's 2Q profit sinks 79 pct but tops forecasts
By LINDA A. JOHNSON - AP - Tue Jul 29, 12:37PM CDT
Pfizer's second-quarter earnings plunged 79 percent from last year, when the world's second-largest drugmaker booked a $10 billion-plus gain from a business spinoff.
Midday Glance: Pharmaceuticals companies
AP - Tue Jul 29, 12:30PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Early Glance: Pharmaceuticals companies
AP - Tue Jul 29, 10:28AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Dow Component Pfizer (PFE) To Go Ex-dividend Tomorrow
at The Street - Tue Jul 29, 10:00AM CDT
Wednesday, July 30, 2014 is the ex-dividend date for Dow component (NYSE FE).
Pfizer Beats on Q2 Earnings, Revs Despite Generic Pressures - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Jul 29, 9:38AM CDT
Pfizer's (PFE) second quarter results were better-than-expected despite several headwinds like generic competition and the expiration of a few co-promotion agreements.
Stocks Climb In Early Trade; Herbalife, El Pollo Loco Dive
at Investor's Business Daily - Tue Jul 29, 9:31AM CDT
Stocks stepped out to healthy gains in solid trade early Tuesday, despite a weaker than expected reading on May home-price growth. The Nasdaq grabbed a 0.5% gain. The Dow Jones industrial average tacked on 0.4% and the S&P 500 moved up 0.3%. Volume...
Q3 Estimates Beginning to Slip - Ahead of Wall Street
Sheraz Mian - Zacks Investment Research - Tue Jul 29, 9:15AM CDT
Lower revisions to the magnitude of Q3 estimates will still be a net positive -- we will see how this trend unfolds.
Stock Market Today: U.S. Stocks Higher as Merck, Pfizer Top Expectations
at The Street - Tue Jul 29, 9:00AM CDT
Major U.S. stock markets open higher on Wall Street Tuesday as investors are greeted by upbeat earnings reports.
Harris & Harris Group Invests in Unique NYC Biotech Accelerator
GlobeNewswire - Tue Jul 29, 7:45AM CDT
Harris & Harris Group, Inc. (Nasdaq:TINY), an investor in transformative companies enabled by disruptive science, today announced that it is one of the founding investors in the expansion of Accelerator Corporation, an investment vehicle for emerging biotechnology companies, into New York City. Accelerator is the result of collaboration between a consortium of top-tier venture capital and corporate investors, scientific thought leaders, and executive managers who will identify, finance and manage the development of a select group of early stage biotechnology companies. As part of its participation, Harris & Harris Group Managing Director Misti Ushio, Ph.D., will join the board of Accelerator in New York City.
Europe shares drift ahead of data; Asia gains
By YURI KAGEYAMA - AP - 37 mins ago
TOKYO (AP) — World markets were mostly higher Wednesday ahead of U.S. economic data while cheery earnings from major Japanese companies such as Honda Motor Co. boosted Asian stocks.
Chronic Plaque Psoriasis - Pipeline Review, H1 2014
M2 - 2 hrs 5 mins ago
Research and Markets (http://www.researchandmarkets.com/research/dpkjk3/chronic_plaque) has announced the addition of the "Chronic Plaque Psoriasis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Plaque Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Plaque Psoriasis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Plaque Psoriasis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Plaque Psoriasis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - AbGenomics International, Inc. - AbbVie Inc. - Actelion Ltd - Almirall, S.A. - ApoPharma Inc. - Biotest AG - Boehringer Ingelheim GmbH - Can-Fite BioPharma Ltd. - Eli Lilly and Company - GlaxoSmithKline plc - Incyte Corporation - Merck & Co., Inc. - Novartis AG - OPKO Health, Inc. - Pfizer Inc. - Sandoz Inc. For more information visit http://www.researchandmarkets.com/research/dp...nic_plaque
Fibromyalgia - Pipeline Review, H1 2014
M2 - 2 hrs 20 mins ago
Research and Markets (http://www.researchandmarkets.com/research/vjrklg/fibromyalgia) has announced the addition of the "Fibromyalgia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Fibromyalgia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fibromyalgia and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Fibromyalgia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Fibromyalgia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Eli Lilly and Company - Merck & Co., Inc. - Dainippon Sumitomo Pharma Co., Ltd. - Meda AB - Pfizer Inc. - Collegium Pharmaceutical, Inc. - Theravance, Inc. - e-Therapeutics plc - Concert Pharmaceuticals, Inc. - SWITCH Biotech LLC - EirGen Pharma Ltd. - Tonix Pharmaceuticals Holding Corp. For more information visit http://www.researchandmarkets.com/research/vj...bromyalgia
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H1 2014
M2 - 2 hrs 27 mins ago
Research and Markets (http://www.researchandmarkets.com/research/djdwhf/cognitive) has announced the addition of the "Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS) and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cognitive Impairment Associated With Schizophrenia (CIAS) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Eli Lilly and Company - Merck & Co., Inc. - Takeda Pharmaceutical Company Limited - Avineuro Pharmaceuticals, Inc. - Novartis AG - FORUM Pharmaceuticals Inc. - H. Lundbeck A/S - Pfizer Inc. - Suven Life Sciences Ltd. - Mithridion, Inc. - CoMentis, Inc. - Upsher-Smith Laboratories, Inc. - Siena Biotech S.p.A. - Dart NeuroScience LLC - Intra-Cellular Therapies, Inc. - Amarantus Bioscience Holdings, Inc. - Mnemosyne Pharmaceuticals, Inc. - SK Biopharmaceuticals Co., Ltd. - AbbVie Inc. - Saniona AB For more information visit http://www.researchandmarkets.com/research/djdwhf/cognitive
Most active New York Stock Exchange-traded stocks
AP - Tue Jul 29, 5:02PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Tue Jul 29, 5:02PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Merck, Pfizer Ramping R&D After Q2 Earnings Beat
at Investor's Business Daily - Tue Jul 29, 4:32PM CDT
Big pharmas Merck and Pfizer modestly beat Q2 estimates early Tuesday, and both guided the full year cautiously as they prepare for new drug launches. Merck stock rose 1.1%, but Pfizer stock fell 1.2%. Merck's (MRK) earnings totaled 85 cents a share,...
After Yesterday's Decline of 1.23%, Pfizer Offers Investors Better Value
Comtex SmarTrend(R) - Tue Jul 29, 3:41PM CDT
Pfizer (NYSE
FE) traded in a range yesterday that spanned from a low of $29.69 to a high of $30.49. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $29.78 on volume of 37.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion. Pfizer Set to Possibly Rebound After Yesterday's Selloff of 1.23%
Comtex SmarTrend(R) - Tue Jul 29, 3:41PM CDT
Pfizer (NYSE
FE) traded in a range yesterday that spanned from a low of $29.69 to a high of $30.49. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $29.78 on volume of 37.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion. Pfizer's 2Q profit sinks 79 pct but tops forecasts
By LINDA A. JOHNSON - AP - Tue Jul 29, 12:37PM CDT
Pfizer's second-quarter earnings plunged 79 percent from last year, when the world's second-largest drugmaker booked a $10 billion-plus gain from a business spinoff.
Midday Glance: Pharmaceuticals companies
AP - Tue Jul 29, 12:30PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Early Glance: Pharmaceuticals companies
AP - Tue Jul 29, 10:28AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Dow Component Pfizer (PFE) To Go Ex-dividend Tomorrow
at The Street - Tue Jul 29, 10:00AM CDT
Wednesday, July 30, 2014 is the ex-dividend date for Dow component (NYSE
FE). Pfizer Beats on Q2 Earnings, Revs Despite Generic Pressures - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Jul 29, 9:38AM CDT
Pfizer's (PFE) second quarter results were better-than-expected despite several headwinds like generic competition and the expiration of a few co-promotion agreements.
Stocks Climb In Early Trade; Herbalife, El Pollo Loco Dive
at Investor's Business Daily - Tue Jul 29, 9:31AM CDT
Stocks stepped out to healthy gains in solid trade early Tuesday, despite a weaker than expected reading on May home-price growth. The Nasdaq grabbed a 0.5% gain. The Dow Jones industrial average tacked on 0.4% and the S&P 500 moved up 0.3%. Volume...
Q3 Estimates Beginning to Slip - Ahead of Wall Street
Sheraz Mian - Zacks Investment Research - Tue Jul 29, 9:15AM CDT
Lower revisions to the magnitude of Q3 estimates will still be a net positive -- we will see how this trend unfolds.
Stock Market Today: U.S. Stocks Higher as Merck, Pfizer Top Expectations
at The Street - Tue Jul 29, 9:00AM CDT
Major U.S. stock markets open higher on Wall Street Tuesday as investors are greeted by upbeat earnings reports.
Harris & Harris Group Invests in Unique NYC Biotech Accelerator
GlobeNewswire - Tue Jul 29, 7:45AM CDT
Harris & Harris Group, Inc. (Nasdaq:TINY), an investor in transformative companies enabled by disruptive science, today announced that it is one of the founding investors in the expansion of Accelerator Corporation, an investment vehicle for emerging biotechnology companies, into New York City. Accelerator is the result of collaboration between a consortium of top-tier venture capital and corporate investors, scientific thought leaders, and executive managers who will identify, finance and manage the development of a select group of early stage biotechnology companies. As part of its participation, Harris & Harris Group Managing Director Misti Ushio, Ph.D., will join the board of Accelerator in New York City.
